Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in self-reported pain levels in participants microdosing GLP1s6 months
Participants will complete an extensive medical questionnaire every 4 weeks over a 24-week period to monitor self-reported pain levels
- Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s6 months
CBC panel will be analyzed every 12 weeks over a 24-week period, reported in thousands of cells per microliter with the change from baseline reported as percent deviation and compared to normalized range of healthy individuals
- Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s6 months
BMP panel will be analyzed every 12 weeks over a 24-week period, reported in mg/dL with the change from baseline reported as percent deviation and compared to a normalized range of healthy individuals
- Change in mood in participants microdosing GLP1s6 months
Mood will be assessed every 4 weeks over a 24-week period using the SF-36 standardized questionnaire with deviation reported as percent change from baseline
- Change in heart rate variability in participants microdosing GLP1s6 months
Participants will wear health devices with data monitored every 4 weeks over a 24-week period to observe change in heart rate variability, being defined as the variability of a participant's resting heart rate. Variability will be measured as an average deviation from baseline heart rate at each timepoint and reported as percent difference.
- Changes in sleep patterns in participants microdosing GLP1s6 months
Wearable health device data will be monitored over the 24-week period assessing REM vs non-REM sleep and reported as a ratio
- Change in frequency of physical activity in participants microdosing GLP1s6 months
The change in frequency of physical activity, defined as a departure from baseline in time spent performing moderate to rigorous physical exercise, will be captured via wearable health device data and will be reported as percent difference from baseline in steps taken.
- Change in frequency of physical activity in participants microdosing GLP1s6 months
The change in frequency of physical activity, defined as a departure from baseline in time spent performing moderate to rigorous physical exercise, will be captured via wearable health device data and will be reported as percent difference from baseline in calories burned.